Results 31 to 40 of about 39,758 (253)

Assessing a 600-mg Loading Dose of Clopidogrel 24 Hours Prior to Pipeline Embolization Device Treatment [PDF]

, 2018
Background: Clopidogrel/aspirin antiplatelet therapy routinely is administered 7-10 days before pipeline aneurysm treatment. Our study assessed the safety and efficacy of a 600-mg loading dose of clopidogrel 24 hours before Pipeline Embolization Device ...
Atallah, MD, Elias, Bekelis, MD, Kimon, Chalouhi, MD, Nohra, Hasan, MD, David, Jabbour, Pascal, MD, Rosenwasser, MD, MBA, FACS, FAHA, Robert H., Saad, MD, Hassan, Smith, MD, Michelle, Tjoumakaris, MD, Stavropoula, Zarzour, MD, Hekmat   +9 more
core   +2 more sources

Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention. [PDF]

, 2017
BackgroundElevated fibrinogen is associated with short-term major adverse cardiovascular events (MACE) after percutaneous coronary intervention, but the relation with late MACE is unknown.Methods and resultsBaseline demographics and 2-year MACE were ...
Ang, Lawrence, Behnamfar, Omid, Lin, Felice, Mahmud, Ehtisham, Palakodeti, Samhita, Patel, Mitul P, Pourdjabbar, Ali, Reeves, Ryan R   +7 more
core   +1 more source

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast, AD Michelson, B Labarthe, B Shen, C Patrono, CT Ammollo, D Capodanno, D Gailani, DA Gorog, Diana A. Gorog, DM Coenen, E Álvarez, ER Bates, F Kabirian, F Müller, F Semeraro, G Stephens, H Brogren, HE Speich, HE Speich, HJ Weiss, HJ Weiss, HR Baumgartner, J Zilberman-Rudenko, JD McFadyen, JI Weitz, JM Cosemans, JP Collet, JP Collet, K Hosokawa, K Nagatsuka, KS Sakariassen, L Valerio, LF Brass, M Cattaneo, M Farag, M Humbert, M Larsson, M Li, M Ungerer, MA Bailey, MI Furman, MJ Price, ML Montfoort von, MS Sabatine, P Andre, P Seizer, PA Borne von dem, PP Wadowski, R Hellmuth, R Nergiz-Unal, RA Ajjan, S Goto, S Goto, SA Shaya, SB Larsen, SJ Marciniak, T Heitzer, T Renné, VT Turitto, VT Turitto, WA Schumacher, WS Nesbitt, X Wang, Y Yano, YC Lau, ZM Ruggeri   +66 more
core   +2 more sources

Can We Override Clopidogrel Resistance? [PDF]

Circulation, 2009
Clopidogrel, a thienopyridine antiplatelet agent, has been used alone or in association with aspirin to prevent vascular complications in atherothrombotic patients. It is also, in combination with aspirin, the key treatment to prevent stent thrombosis in patients who have undergone percutaneous coronary intervention.
Ana, Pena, Jean-Philippe, Collet, Jean-Sébastien, Hulot, Johanne, Silvain, Olivier, Barthélémy, Farzin, Beygui, Christian, Funck-Brentano, Gilles, Montalescot   +7 more
openaire   +2 more sources

Impaired glucose tolerance or newly diagnosed diabetes mellitus diagnosed during admission adversely affects prognosis after myocardial infarction: An observational study [PDF]

, 2015
Objective To investigate the prognostic effect of newly diagnosed diabetes mellitus (NDM) and impaired glucose tolerance (IGT) post myocardial infarction (MI).
Beer, Stephen F., Bhatia, Raghav T., Buchanan, Gill L., Chattopadhyay, Sudipta, George, Anish, John, Joseph, Moisey, Robert S., Sathyapalan, Thozhukat, Whiteside, Anne   +8 more
core   +9 more sources

Ticagrelor Use in Indian Patients Undergoing Neuroendovascular Procedures: A Single Center Experience [PDF]

Neurointervention, 2019
Purpose A safe and efficacious antiplatelet drug is needed for patients with clopidogrel resistance who undergo neuroendovascular procedures. Ticagrelor is a new reversibly binding, oral, direct-acting P2Y receptor antagonist with no known resistance. We
Vivek Karan, Devashish Vyas, Vikram Bohra, Vikram Huded   +3 more
doaj   +1 more source

Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]

, 2019
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A, Gue, Ying X, Kanji, Rahim, Srinivasan, Manivannan, Wellsted, David M, Wyatt, Solange   +5 more
core   +2 more sources

Effect of obesity and serum leptin level on clopidogrel resistance

Türk Kardiyoloji Derneği Arşivi, 2016
Objective: Clopidogrel inhibits platelet aggregation by blockade of platelet adenosine diphosphate (ADP) P2Y12 receptor. Leptin is the obesity gene product, and its serum level increases with obesity.
Ali Dogan, Serkan Kahraman, Emrah Usta, Emrah Ozdemir, Uzay Gormus, Cavlan Ciftci   +5 more
doaj   +1 more source

Clinical application of high throughput molecular screening techniques for pharmacogenomics. [PDF]

, 2011
Genetic analysis is one of the fastest-growing areas of clinical diagnostics. Fortunately, as our knowledge of clinically relevant genetic variants rapidly expands, so does our ability to detect these variants in patient samples.
Schrijver, Iris, Wiita, Arun P
core   +1 more source

ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION

Рациональная фармакотерапия в кардиологии, 2016
Aim. To evaluate the incidence of acetylsalicylic acid (ASA) and clopidogrel resistance in patients with acute coronary syndrome with ST-segment elevation and to find out possible clinical factors, contributing to this state.Material and methods.
D. H. Ainetdinova, A. Е. Udovichenko, V. A. Sulimov   +2 more
doaj   +1 more source